Telix Pharmaceuticals has reaffirmed its financial guidance for fiscal year 2026, projecting that total income will exceed US$1 billion. This figure combines expected core revenue of US$950 million to US$970 million with US$40 million in other income received from Regeneron.

The company stated that revenue is progressing in line with the upper end of its guidance range. The inclusion of the Regeneron payment allows the total income threshold to be crossed, while the core commercial performance drives the primary revenue band.

Financial Outlook

R&D Expenditure

Telix has maintained its research and development expenditure guidance at US$230 million to US$270 million for the fiscal year. The company noted that this spending level is enabled by its strong commercial performance and the initial payment received from Regeneron.

What the Numbers Show

The FY26 guidance highlights a significant reliance on non-operating income to breach the US$1 billion total income milestone. With core revenue capped at US$970 million at the upper end of the guidance, the US$40 million payment from Regeneron constitutes a critical component of the top-line achievement. This structure indicates that while commercial operations are tracking toward the higher end of expectations, the headline total income figure is materially supported by this specific external inflow rather than organic sales growth alone.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) reported robust financial results for the half-year ended June 30, 2026, with group revenue rising 22% year-over-year to US$477 million. This performance tracks in line with the upper end of its full-year guidance of US$950 million to US$970 million.

Adjusted EBITDA surged 146% to US$52 million, supported by solid commercial execution across its product portfolio and an initial non-refundable payment of US$40 million from its strategic collaboration with Regeneron. Profit after tax stood at US$38 million, compared to a loss of US$2 million in the prior period.

Financial Performance

The company’s gross margin improved by 2 percentage points to 55%, while the Precision Medicine segment achieved a 65% gross margin, up 1 percentage point year-over-year. These improvements reflect favorable product mix and operational efficiencies.

Research and development investment totaled US$124 million, primarily directed toward late-stage therapeutic and precision medicine programs. Operating cash flow was positive at US$23 million, and the company maintained a cash balance of US$252 million as of June 30, 2026.

Segment Highlights

The Precision Medicine segment saw revenue grow 27% year-over-year, driven by volume growth and market share gains for Illuccix and Gozellix. Adjusted segment EBITDA for this division rose 26% to US$132 million.

In Telix Manufacturing Solutions (TMS), total segment revenue reached US$146 million, comprising US$89 million from third-party sales and service fees. The segment reported an operating loss of US$33 million, including US$10 million in depreciation and amortization on acquired intangibles.

Balance Sheet and Pipeline Progress

Telix completed the refinancing of its existing convertible bond structure, issuing US$600 million of new convertible bonds due 2031. Finance costs for the period were US$19 million, predominantly related to this refinancing.

Clinical milestones included:

• Patient enrollment nearing completion for the Phase 3 BiPASS study of Illuccix and Gozellix.
• FDA acceptance of the New Drug Application for Illuccix in China.
• FDA clearance for Pixclara Phase 3 IND application to explore indication expansion to brain metastases diagnosis.
• First patient dosed in LUTEON, a pivotal trial of TLX250-Tx in advanced clear cell renal cell carcinoma.

What the Numbers Show

The profitability turnaround is heavily influenced by non-operational items. While operating profit increased from US$10 million to US$46 million, the reported profit after tax of US$38 million includes US$40 million in other income from Regeneron. Without this one-time payment, the underlying operational profit would be significantly lower, highlighting the dependency on collaboration milestones for near-term bottom-line strength despite strong top-line growth.